Search This Blog

Thursday, June 18, 2026

NovoCure's Phase 3 misses primary endpoint

 

NovoCure's Phase 3 TRIDENT trial in newly diagnosed glioblastoma fails to improve survival with earlier Tumor Treating Fields, misses primary endpoint

  • Topline Phase 3 TRIDENT data showed earlier Tumor Treating Fields initiation versus standard timing did not improve overall survival.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)